DAFNA Capital Management »

Rapport Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $2.3M 75k 30.34
2025-09-30 $2.2M 75k 29.70

More positions owned by DAFNA Capital Management

Revolution Medicines (RVMD)
Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
AtriCure (ATRC)
Cytokinetics Com New (CYTK)
Ideaya Biosciences (IDYA)
Axogen (AXGN)
Xenon Pharmaceuticals (XENE)
Ishares Nasdaq Biotech Indx Etf (IBB)
Biohaven (BHVN)
Arcus Biosciences Incorporated (RCUS)
Neurocrine Biosciences (NBIX)
Day One Biopharmaceuticals I (DAWN)
Tandem Diabetes Care Com New (TNDM)
Ascendis Pharma A/s Sponsored Adr (ASND)

View all positions for DAFNA Capital Management

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
BlackRock
Sofinnova Ventures
Vanguard Group
Johnson & Johnson
Baker Bros. Advisors
Vestal Point Capital
Polar Capital Holdings
Trv Gp Vi
Ubs Global Asset Management Americas

View all funds holding Rapport Therapeutics